Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Journey Medical Corp ( (DERM) ) is now available.
On April 21, 2026, Journey Medical announced that approximately 85% of all U.S. commercial lives now have access to its rosacea treatment Emrosi, after securing a contract with a third major group purchasing organization. The new agreement expanded Emrosi’s commercial payer access from about 100 million to more than 150 million covered lives as of April 1, 2026, bolstering the drug’s launch trajectory and positioning it for broader formulary adoption and improved brand profitability as reliance on co-pay support decreases.
Management framed the expanded access as a key milestone in Journey Medical’s strategy to make cost-effective dermatology therapies more widely available. The company expects that deeper national and regional health-plan formulary penetration throughout 2026 will support Emrosi’s bid to become a standard treatment for inflammatory lesions of rosacea, potentially enhancing long-term value for the brand and reinforcing Journey Medical’s competitive standing in the dermatology market.
The most recent analyst rating on (DERM) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Journey Medical Corp stock, see the DERM Stock Forecast page.
Spark’s Take on DERM Stock
According to Spark, TipRanks’ AI Analyst, DERM is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses and negative recent cash flow) and very bearish technicals (price far below key moving averages with negative MACD). Offsetting these, the latest earnings call was constructive with strong Emrosi launch metrics and guidance to remain adjusted EBITDA positive, while valuation is difficult to assess due to negative earnings and no dividend.
To see Spark’s full report on DERM stock, click here.
More about Journey Medical Corp
Journey Medical Corporation, based in Scottsdale, Ariz., is a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription products for dermatological conditions. The company currently markets eight branded dermatology drugs in the U.S., leveraging an efficiency-focused sales and marketing model to build a portfolio of skin-health therapies.
Average Trading Volume: 206,184
Technical Sentiment Signal: Sell
Current Market Cap: $144.9M
For detailed information about DERM stock, go to TipRanks’ Stock Analysis page.